On April 26, 2024, Cancer Diagnosis and Treatment Quality Monitoring and Management Meeting was held in Beijing. The award ceremony of Excellent Data Quality Affiliation of National Anti-Tumor Drug Surveillance System was also held. 78 hospitals with Grade A national data quality received the award. The First Affiliated Hospital (FAH) of Xi'an Jiaotong University (XJTU) was awarded as Excellent Data Quality Affiliation of National Anti-Tumor Drug Surveillance System. Cancer Center and Department of Network Information of FAH are responsible for business and technological support for National Anti-Tumor Drug Surveillance System.

National Anti-Tumor Drug Surveillance System is established by National Cancer Center according to the Notification on Monitoring Clinical Application of Anti-tumor Drugs in China issued by National Health Commission, which continuously monitors the purchase and use information of anti-tumor drugs and clinical diagnosis and treatment information of cancer patients in 1526 medical institutions from 31 provinces (autonomous regions and municipalities directly under the Central Government) and Xinjiang Production and Construction Corps, analyzes and publicizes 12 indexes from three perspectives including the accessibility and rationality of clinical application of anti-tumor drugs and medical quality management and control in all medical institutions on a yearly basis, and establishes a long-term mechanism for monitoring clinical application of anti-tumor drugs and comprehensive evaluation of standardized diagnosis and treatment management of tumors. Moreover, National Anti-Tumor Drug Surveillance System serves as the data source platform of quality control indexes for oncology specialty in the Operational Manual for Performance Appraisal of National Tertiary Public Hospitals (2024), and relevant data will also be utilized as important data source for subsequent evaluation of clinical specialty capacity by National Health Commission this year. The first batch will focus on lung cancer, breast cancer and liver cancer.

The meeting consists of "Exploration of innovative practice of quality control management in specialty departments" and "Promoting the improvement of medical quality in oncology specialty in an orderly manner". All hospitals shared and discussed how specialty and general hospitals can effectively manage the quality of tumor diagnosis and treatment by multidisciplinary team diagnosis and treatment model, information platform, management assessment mechanism and performance-based lever after medical quality control indexes of oncology specialty were included in the "national evaluation". They also shared and exchanged the application of different strategies such as single-disease MDT diagnosis and treatment mode, AI technology, PDCA tool and PDSA-SDCA dual-cycle mode to better improve the evaluation rate of clinical TNM staging before tumor treatment and accelerate the implementation of national medical quality and safety improvement goals. At present, Cancer Center of FAH, along with Department of Network Information, has launched and put into trial operation of "Platform for Standardization of Cancer Diagnosis and Treatment and Rationalization of Expenses" as the quality control platform for single tumor diseases in FAH. The first batch comprises 10 cancer diseases (breast cancer, lung cancer, liver cancer, colorectal cancer, gastric cancer, esophageal cancer, prostate cancer, cervical cancer, ovarian cancer and pancreatic cancer), which will better achieve real-time monitoring of the quality of diagnosis and treatment process, suggestions for standardized diagnosis and treatment of tumors, real-time quality analysis and multi-dimensional decision analysis of tumor diagnosis and treatment management in the entire hospital, promoting the improvement of medical quality control indexes and the realization of medical quality and safety improvement goals for oncology discipline in the "national evaluation".